Picture: Oxurion nv

Oxurion: CFO now CEO

Tom Graney, until now CFO of Belgian Oxurion nv, took over from CEO Patrik De Haes. De Haes becomes Non-executive Chairman of the Biopharmaceutical company, spezialised in retinal disorders.

Graney just started in October 2020 as Oxurion’s Chief Financial Officer. He has extensive experience in corporate development, commercial strategy, portfolio management and supply chain management, communication and investor relations. He served as CFO in several companies, including Generation Bio, Ethicon, Tibotec and Janssen. In addition to his role as CFO, he was Senior Vice President at Vertex Pharmaceuticals Inc., and Senior Vice President of Finance & Corporate Strategy at Ironwood Pharmaceuticals. Prior to Ironwood Pharmaceuticals, Graney spent 20 years with J&J.

The new CEO holds a B.S. in accounting from the University of Delaware and an M.B.A. in Marketing, Finance and International Business from the Leonard N. Stern School of Business at New York University.

After 14 years as CEO Dr Patrik De Haes has decided to leave the day-to-day management and to become the Non-executive Chairman of Oxurion. The outgoing Chairman of the company, Thomas Clay, will remain on the Board as a Non-executive Director.